<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="6405">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03023540</url>
  </required_header>
  <id_info>
    <org_study_id>CLN-PXT3003-03</org_study_id>
    <secondary_id>2015-002379-81</secondary_id>
    <nct_id>NCT03023540</nct_id>
  </id_info>
  <brief_title>Assessing Long Term Safety and Tolerability of PXT3003 in Patients With Charcot-Marie-Tooth Disease Type 1A</brief_title>
  <acronym>PLEO-CMT-FU</acronym>
  <official_title>International, Multi-center, Double Blind 9-month Follow-up Extension Study Assessing the Long Term Safety and Tolerability of PXT3003 in Patients With Charcot-Marie-Tooth Disease Type 1A</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pharnext SA</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>SynteractHCR</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>INC Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Pharnext SA</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      All randomised patients with Charcot-Marie-Tooth Type 1A (CMT1A) who completed the primary
      study CLN-PXT3003-02, i.e. 15-month double-blind treatment with PXT3003 or placebo, will be
      eligible to continue in the extension study CLN-PXT3003-03.

      Patients randomised to PXT3003 dose 1 or 2 in the primary study (CLN-PXT3003-02) will
      continue in the extension study at the same dose, while the patients who received placebo
      will be assigned to one of the two active doses by a second randomization at the entry in
      the extension study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PXT3003 is a rational design, fixed combination of low-dose (RS) baclofen, naltrexone
      hydrochloride and D-sorbitol. The use of PXT3003 in a multicenter, randomised, placebo
      controlled phase II study (CLN-PXT3003-01) was well-tolerated and safe in patients with
      CMT1A for the three dose-levels investigated (Attarian et al., 2014). The intermediate and
      high dose of PXT3003 demonstrated an improvement of disability in this patient population.

      Subsequently a a multicenter, randomised, placebo controlled phase III study
      (CLN-PXT3003-02) to assess the efficacy and safety of PXT3003 in the treatment of patients
      with CMT1A was initiated in December 2015. In March 2017 the first patients will have
      completed the 15-month treatment with PXT3003. Thereafter, patients will be allowed for
      entry in this extension study (CLN-PXT3003-03) for a 9-month treatment with PXT3003. Thus
      patients initially randomised to active treatment will have used PXT3003 for 24 months,
      whereas patients initially randomized to inactive treatment will have used PXT3003 for 9
      months.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 7, 2017</start_date>
  <completion_date type="Anticipated">January 2019</completion_date>
  <primary_completion_date type="Anticipated">January 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Participant, Care Provider, Investigator, Outcomes Assessor</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of treatment-emergent adverse events (TEAEs) related to PXT3003 during the follow-up in patients with CMT1A</measure>
    <time_frame>9 or 24 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of all TEAEs and their evaluation of type/nature, severity/intensity, seriousness, duration, relationship to study drug, and outcome</measure>
    <time_frame>9 or 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events leading to withdrawal of study drug</measure>
    <time_frame>9 or 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Neuropathy Limitation Scale (ONLS) score, and its arm and leg sub-items</measure>
    <time_frame>9 or 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Charcot-Marie-Tooth Neuropathy Score - version 2 (CMTNS-V2), and its sub-items</measure>
    <time_frame>9 or 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nine-hole Peg Test (9-HPT)</measure>
    <time_frame>9 or 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quantified Muscular Testing (QMT) by hand grip and foot dorsiflexion dynamometry (mean of both sides)</measure>
    <time_frame>9 or 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to walk 10 meters</measure>
    <time_frame>9 or 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compound Muscle Action Potential (CMAP) on ulnar nerve</measure>
    <time_frame>9 or 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sensory Nerve Action Potential (SNAP) on radial nerve</measure>
    <time_frame>9 or 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nerve conduction velocity (NCV)</measure>
    <time_frame>9 or 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>9 or 24 months</time_frame>
    <description>EuroQol 5-Dimensional Health-related Quality of Life scale (EQ-5D</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual analog scale on self-assessment of individualized main impairment in daily activities (defined at baseline with the patient)</measure>
    <time_frame>9 or 24 months</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Through plasma concentration of PXT3003</measure>
    <time_frame>at month 6 and 9</time_frame>
    <description>Measurement of baclofen, naltrexone and 6-beta-naltrexone plasma concentration at the through</description>
  </other_outcome>
  <other_outcome>
    <measure>Peak plasma concentration of PXT3003</measure>
    <time_frame>at month 6 and 9</time_frame>
    <description>Measurement of baclofen, naltrexone and 6-beta-naltrexone plasma concentration at the through</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">323</enrollment>
  <condition>Charcot-Marie-Tooth Disease, Type IA</condition>
  <arm_group>
    <arm_group_label>PXT3003 dose 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>PXT3003: Liquid oral solution, 5 mL bid (taken morning and evening with food) for 9 consecutive months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PXT3003 dose 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>PXT3003: Liquid oral solution, 5 mL bid (taken morning and evening with food) for 9 consecutive months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PXT3003</intervention_name>
    <description>Liquid oral solution, 5 mL bid for 9 consecutive months</description>
    <arm_group_label>PXT3003 dose 1</arm_group_label>
    <arm_group_label>PXT3003 dose 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients must have completed 15 months of double-blind treatment in the primary study
             CLN-PXT3003-02, including all procedures required at the Study Termination visit (V6)

          -  Female patients must agree to continue using an approved method of birth control
             throughout the extension study

          -  Patients must sign a written informed consent, specific to the extension study, in
             order to participate in this study. In case of minor children aged 16 to 18 years,
             both parent' and children's consents should be collected

        Exclusion Criteria:

          -  Any clinically significant change in health status that, in the opinion of the
             Investigator, would prevent the subject from participating in this study or
             successfully completing this study

          -  Any unauthorized concomitant treatments, as study CLN-PXT3003-02 (e.g. including but
             not limited to baclofen, naltrexone,sorbitol (pharmaceutical form), opioids,
             levothyroxin, and potentially neurotoxic drugs such as amiodarone, chloroquine,
             cancer drugs susceptible to induce peripheral neuropathy)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>67 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shahram Attarian, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU la Timone, Marseille, France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Peter Young, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Munster, Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Teresa Sevilla, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario i Politécnico La F, Valencia, Spain</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marianne de Visser, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Academic Medical Center, Amsterdam, Netherlands</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mark Roberts, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Selor Royal NHS Foundation Trust, Manchester, UK</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Florian Thomas, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seton Hall-Hackensack-Meridian School of Medicine, Hackensack, USA</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rene Goedkoop, MD</last_name>
    <phone>+33 1 41 09 22 30</phone>
    <email>rgoedkoop@pharnext.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Daniel Cohen, MD PhD</last_name>
    <phone>+33 1 41 09 22 30</phone>
    <email>dcohen@pharnext.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Neurology, Cedars-Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Robert H Baloh, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital for Special Care, New Britain</name>
      <address>
        <city>New Britain</city>
        <state>Connecticut</state>
        <zip>06053</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kevin Felice, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department of Neurology, McKnight Brain Institute</name>
      <address>
        <city>Gainsville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>S H Subramony, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Kansas Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jeffrey Statland, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anthony A Amato, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Michigan Health System</name>
      <address>
        <city>Ann Harbor</city>
        <state>Michigan</state>
        <zip>48109-5322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sindhu Ramchandren, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department of Neurology, University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>David Walk, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department of Neurology and Psichiatry, Saint Louis University</name>
      <address>
        <city>St Louis</city>
        <state>Missouri</state>
        <zip>63104-1027</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jafar P Kafaie, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Peripheral Neuropathy Center, Neurological Institue Building, Columbia University Medical Center</name>
      <address>
        <city>New-York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Thomas H Brannagan, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stanley Iyadurai, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Saint Luke's Rehabilitation Institute</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99202-1330</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gregory T Carter, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Departement of Neurology, UZ Leuven</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Philip Van Damme, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital of Quebec</name>
      <address>
        <city>Quebec</city>
        <zip>G1J 1Z4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jack Puymirat, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cntre de Reference des Maladies Neuromusculaires, Hopital Swynghedauwl, CHU Lille</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Margueritte Preudhomme, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre de Reference des Neuropathies Peripheriques Rare, Hopital Dupuytren, CHU Limoges</name>
      <address>
        <city>Limoges</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurent Magy, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Service de Neurologie et du Sommeil, CHU Lyon Sud</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pierre-Marie Gonnaud, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre de Reference des Maladie Neuromusculaires, CHU la Timone</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shahram Attarian, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre de Reference des Maladie Neuromusculaires, Hotel Dieu, CHU de Nantes</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yann Péréon, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Service de Neurologie, Hopital Kremlin Bicetre</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>David Adams, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department of Neurology and Institute for Neuropathology, University Hospital RWTH Aachen</name>
      <address>
        <city>Aachen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Burkhard Gess, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department of Clinical Neurophysiology, University Medical Center Göttingen</name>
      <address>
        <city>Gottingen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dirk Czesnik, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department of Neurology, Ludwig-Maximillian University, Munich</name>
      <address>
        <city>Munich</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Maggie Walter, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department for Sleep Medicine and Neuromuscular disease, University Hospital Münster</name>
      <address>
        <city>Munster</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Peter Young, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Departement of Neurology, Academic Medical Center</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marianne de Visser, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department of neurology, Hospital Univesitario de Bellvitge</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Carlos Casasnovas, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Servicio de Neurologia, Hospital Universitario La Paz</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ignacio Pascual, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centro de Diagnostico y Tratamiento, Hospital Universitario Virgen del Rocio</name>
      <address>
        <city>Sevilla</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Celedonio Marquez, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Servicio de Neurologia, Hospital Universitario i Politécnic La Fe</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Teresa Sevilla, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department of Neurology, Salford Royal NHS Foundation Trust</name>
      <address>
        <city>Salford</city>
        <state>Manchester</state>
        <zip>M6 8HD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mark Roberts, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <lastchanged_date>April 7, 2017</lastchanged_date>
  <firstreceived_date>December 26, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Charcot Marie Tooth Type 1A</keyword>
  <keyword>Peripheral neuropathy</keyword>
  <keyword>PXT3003</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Tooth Diseases</mesh_term>
    <mesh_term>Charcot-Marie-Tooth Disease</mesh_term>
    <mesh_term>Nerve Compression Syndromes</mesh_term>
    <mesh_term>Hereditary Sensory and Motor Neuropathy</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
